雷帕鸣西罗莫司片有什么注意事项吗

In September 1999, it was approved by the US FDA and officially launched on the market. Sirolimus (sirolimus tablets) is mainly used to prevent and treat rejection of kidney, liver and other transplants, especially for patients with renal dysfunction, tremor and hypertension. Rapamin (sirolimus) has low oral bioavailability, large inter-individual pharmacokinetic (PK) differences, and is a substrate of CYP3A and P glycoprotein (PgP), which can cause drug-drug interactions with a variety of drugs.

Are there any precautions for taking Sirolimus Tablets?

Rapamin (sirolimus) is recommended for oral administration once daily in combination with cyclosporine and corticosteroids. To reduce differences in the absorption of rapamycin, patients should choose to take it regularly with or without food. Tablets should not be broken or chewed.

  Allergic reactions, including angioedema, exfoliative dermatitis and hypersensitivity vasculitis, have been reported during the treatment of rapamin (sirolimus). Patients should discontinue the drug and seek medical attention immediately when they experience the above reactions. Because immunosuppression may also increase the risk of infection, including activation of latent viral infections (including BK virus-related nephropathy), fatal infections, and sepsis, patients need to take preventive measures against related diseases after taking the drug.

  Treatment with rapamin (sirolimus tablets, sirolimus) may cause harm to the fetus. Therefore, effective contraceptive measures should be taken during treatment with rapamin (sirolimus tablets) and for 12 weeks after stopping. During pregnancy, rapamirumab should be used only if the potential benefits of its use outweigh the potential risks to the embryo/fetus.

The above is the introduction about it, I hope it can help everyone. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/82416.html